Phase II Study of LBH589 for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome.
Phase of Trial: Phase II
Latest Information Update: 25 Jun 2015
At a glance
- Drugs Panobinostat (Primary)
- Indications Myelodysplastic syndromes
- Focus Therapeutic Use
- 01 Jun 2013 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 06 Nov 2012 Planned end date changed from 1 Dec 2013 to 1 Dec 2014 as reported by ClinicalTrials.gov.
- 16 Mar 2011 Status changed from recruiting to active, no longer recruiting as reported by M.D. Anderson Cancer Center.